Enpatoran, a Toll-like receptor 7/8 inhibitor, in moderate-to-severe systemic lupus erythematosus: findings from Cohort B of a multicentre, international, double-blind, placebo-controlled dose-finding phase 2 trial

Journal:

The Lancet

Published:

2026-05-09

DOI:

10.1016/s0140-6736(26)00463-0

Affiliations:

13

Authors:

14

Go to article

Institutions	Authors	Share
Merck Group, Germany	4.000000	0.29
EMD Serono, Inc., United States of America (USA)	2.000000	0.14
Monash University, Australia	1.000000	0.07
University of California, San Francisco (UCSF), United States of America (USA)	1.000000	0.07
University of Minnesota (UMN), United States of America (USA)	1.000000	0.07
University Hospital Bonn (UKB), Uni Bonn, Germany	1.000000	0.07
Ares Trading S.A., Switzerland	1.000000	0.07
Northwell Health, United States of America (USA)	1.000000	0.07
Mount Sinai Hospital (MSH), U of T, Canada	0.500000	0.04
Toronto Western Hospital (TWH), U of T, Canada	0.500000	0.04
University of Pennsylvania (Penn), United States of America (USA)	0.500000	0.04
Corporal Michael J. Crescenz VA Medical Center (CMCVAMC), United States of America (USA)	0.500000	0.04

Interested in Clinical Sciences?